3 results match your criteria: "Shanxi Da Yi Hospital of Shanxi Medical University[Affiliation]"
[Comparison of IA and HAD for induction remission therapy of FLT3-ITD positive acute myeloid leukemia patients].
Zhonghua Xue Ye Xue Za Zhi
April 2019
Department of Hematology, Shanxi Da Yi Hospital of Shanxi Medical University, Taiyuan 030032, China.
Factors affecting the CD34 cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor.
Transfus Apher Sci
December 2016
Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China. Electronic address:
Background: A second allogeneic hematopoietic stem-cell transplantation and donor lymphocyte infusion using cells from the same donor is a therapeutic option in the case of stem-cell graft failure or disease relapse, but little is known about the factors associated with the CD34 cell yields from second donations.
Methods: One-hundred healthy donors who underwent a second mobilization treatment and peripheral blood stem-cell (PBSC) collection were studied. For both mobilization processes, 5 µg of granulocyte colony-stimulating factor per kg per day was administered.
[The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi
November 2014
Department of Hematology, Shanxi Da Yi Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, China.
Objective: To investigate the efficacy and toxicity of modified FLAG and CAG on relapsed or refractory acute myeloid leukemia (AML).
Methods: Sixty-one patients with relapsed or refractory AML were divided into modified FLAG or CAG group. In modified FLAG group: G-CSF 200 μg·m⁻²·d⁻¹ on days 0-5; fludarabine 30 mg·m⁻²·d⁻¹ on days 1-5; Ara-C 1.